ClinicalTrials.gg
CompletedNCT03281356Updated Sep 13, 2017

Text Messaging Pilot Study

An interventional study of Intervention Group in Literacy, sponsored by Rutgers, The State University of New Jersey. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-09-13.

Sponsored by Rutgers, The State University of New Jersey · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled May 2017, registered Sep 2017).
Phase
Not applicable
Study type
Interventional
Enrollment
16
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This pilot study aims to assess the acceptability, feasibility, and preliminary effectiveness of text messages designed to encourage shared reading among urban parents. We hypothesize that parents will report reading more often to their children after receiving the text messages.

Read the detailed description

This is a single arm, pilot study. The participants enrolled will receive two text messages per week for a 4 week period (a total of 8 messages). At the end of the study period we will assess change in number of reading occurrences using a validated measure. Parents will also complete a brief acceptability survey.

02

Conditions studied

  • Literacy

Browse trials for

Keywords

  • Pilot Study
  • Early childhood development
03

In context

Literacy

201 studies on the registry are indexed under Literacy; 69 are open to participants now.

This study's enrollment of 16 is below the median of 124 across 170 interventional studies indexed under Literacy.

Browse Literacy studies →

Lead sponsor

Rutgers, The State University of New Jersey is the lead sponsor of 506 studies on the registry; 131 are open to participants now.

Of its 39 completed or terminated interventional studies of FDA-regulated products, 31 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Preferred language either English or Spanish,
  2. Parent or legal guardian,
  3. Age ≥ 18,
  4. Willing to accept text messages

Exclusion criteria

Exclusion Criteria:

  1. Individuals unable to provide consent
  2. Individuals who do not meet inclusion criteria
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Intervention Group

    Behavioral: Intervention Group

Interventions

  • BehavioralIntervention Group

    Participants will receive a total of 8 text messages during a 4 week period.

06

What researchers measure

Primary outcomes

  1. Acceptability Survey

    Three questions on the participants feedback on the program.

    Time frame: Visit 2 (1 month)

Secondary outcomes

  1. Stim Q Survey

    The StimQ is a parent reported measure of the cognitive home environment

    Time frame: Visit 2 (1 month)

07

Study locations

1 site
  • Rutgers Robert Wood Johnson Medical School
    New Brunswick, New Jersey 08901, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2017 to primary completion in Jun 2017, 1 month.

Of 115 non-industry interventional studies with no phase under Literacy, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 20. This study's 1 month is below that.

Counting every sponsor, half of 117 studies reached it within 11 months; a quarter within 4 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2017
First posted
Sep 13, 2017
StartActual
May 9, 2017
Primary completionActual
Jun 13, 2017
CompletionActual
Jun 13, 2017
Last update
Sep 13, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 13, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03281356
Responsible party
Manuel E. Jimenez, MD, MS (Assistant Professor, Rutgers, The State University of New Jersey) — Principal investigator
First posted
Sep 13, 2017
Start date
May 9, 2017
Primary completion
Jun 13, 2017
Completion
Jun 13, 2017
Last update
Sep 13, 2017

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion